Changes in energy metabolism of calf muscle in patients with intermittent claudication assessed by 31P magnetic resonance spectroscopy: A phase II open study

Vascular Medicine

Volumn 1, Issue 4, 1996, Pages 241-245

  Taylor, D J ^a   Amato, A ^b   Hands, L J ^a,c   Kemp, G J ^a,d   Ramaswami, G ^b   Nicolaides, A ^b   Radda, G K ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

31P MRS; Energetics; Muscle metabolism; Peripheral arterial disease; pH; Propionyl L carnitine

Indexed keywords

CREATINE PHOSPHATE; PHOSPHORUS 31; PROPIONYLCARNITINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVITY; EXERCISE; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKELETAL MUSCLE;

EID: 0030444753     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X9600100401     Document Type: Article

References (17)

1. 31P nuclear magnetic resonance spectroscopy. Clin Sci 1986; 71: 283-90.
2. 31P magnetic resonance spectroscopy. Clin Sci 1995; 89: 581-90.
3. Brevetti G, Angelini C, Rosa M et al. Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation 1991; 84: 1490-95.
4. Brevetti G, Chiariello M, Ferulano G et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988; 77: 767-73.
5. Brevetti G, Perna S, Sabba C et al. Superiority of L-propionylcamitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J 1992; 13: 251-55.
6. Coto V, D'Alessandro L, Grattarola G et al. Evaluation of the therapeutic efficacy and tolerability of levocarniline propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs Exp Clin Res 1992; 18: 29-36.
7. Durnin JVGA, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness; measurements in 481 men and women aged from 16 to 72 years. Brit J Nutr 1974; 32: 77-97.
8. Arnold DL, Taylor DJ, Radda GK. Investigations of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. Ann Neurol 1985; 18: 189-96.
9. Pernow B, Saltin B, Wahren J, Cronestrand R, Ekestrom S. Leg blood flow and muscle metabolism in occlusive arterial disease of the leg before and after reconstructive surgery. Clin Sci 1975; 49: 265-75.
10. Bylund-Fellenius AC, Walker PM, Elander ASH, Holm S, Holm J, Schersten T. Energy metabolism in relation to oxygen partial pressure in human skeletal muscle during exercise. Biochem J 1981; 200: 247-55.
11. Veech R, Lawson J, Cornell N, Krebs H. Cytosolic phosphorylation potential. J Biol Chem 1979; 254: 6538-47.
12. Kemp GJ, Taylor DJ, Radda GK. Control of phosphocreatine resynthesis during recovery from exercise in human skeletal muscle. NMR Biomed 1993; 6: 66-72.
13. + antiport activity in exercising skeletal muscle of patients with essential hypertension detected by phosphorus magnetic resonance spectroscopy. Clin Sci 1990; 79: 491-97.
14. Brevetti G, Perna S, Sabba C, Martone VD, Condorelli M. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 1995; 26: 1141-46.
15. Brevetti G, di Lisa F, Perna S et al. Carnitine-related alterations in patients with intermittent claudication. Circulation 1996; 93: 1685-1701.
16. Taylor DJ, Kemp GJ, Radda GK. Bioenergetics of skeletal muscle in mitochondrial myopathy. J Neurol Sci 1994; 127: 198-206.
17. 31P MRS of abnormal mitochondrial oxidative in skeletal muscle during recovery from exercise. NMR Biomed 1993; 6: 302-10.